Coronary Artery Disease
|
0.200 |
Biomarker
|
disease |
BEFREE |
Plasminogen activator inhibitor type-1 (PAI-1) is a <u>ser</u>ine <u>p</u>rotease <u>in</u>hibitor (serpin) implicated in numerous pathological processes, including coronary heart disease, arterial and venous thrombosis, and chronic fibrotic diseases.
|
30510136 |
2019 |
Coronary Artery Disease
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Compared with the control group, the CAD group displayed significantly higher serum levels of retinol-binding protein-4 (RBP4), pentraxin 3 (PTX3), galectin-3 (GAL-3), and plasminogen activator inhibitor (PAI-1), and significantly lower levels of netrin-1 (NTN1), interleukin-37 (IL-37), and adiponectin (ADP) (all P < 0.05).
|
31464731 |
2019 |
Coronary Artery Disease
|
0.200 |
Biomarker
|
disease |
BEFREE |
In 106 stable CAD subjects undergoing intravascular ultrasound with virtual histology (IVUS-VH), we measured D-dimer, lipoprotein(a) (Lp(a)), plasminogen, biomarkers reflecting oxidation-specific epitopes (OSE) such as oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB), OxPL on plasminogen (OxPL-PLG), and autoantibodies to phosphorylcholine-BSA [PC-BSA] and a malondialdehyde [MDA] mimotope.
|
29344841 |
2018 |
Coronary Artery Disease
|
0.200 |
Biomarker
|
disease |
BEFREE |
Soluble Urokinase Plasminogen Activator Receptor and the Risk of Coronary Artery Disease in Young Chinese Patients.
|
29109596 |
2017 |
Coronary Artery Disease
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Causal Effect of Plasminogen Activator Inhibitor Type 1 on Coronary Heart Disease.
|
28550093 |
2017 |
Coronary Artery Disease
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The study further provides evidence that in addition to PLG, the currently known shared susceptibility loci of CAD and periodontitis, ANRIL and CAMTA1/VAMP3, are subjected to transforming growth factor-β regulation.
|
25466412 |
2015 |
Coronary Artery Disease
|
0.200 |
GeneticVariation
|
disease |
GWASCAT |
A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease.
|
26343387 |
2015 |
Coronary Artery Disease
|
0.200 |
Biomarker
|
disease |
BEFREE |
Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease.
|
24253546 |
2014 |
Coronary Artery Disease
|
0.200 |
GeneticVariation
|
disease |
GWASDB |
Large-scale association analysis identifies new risk loci for coronary artery disease.
|
23202125 |
2013 |
Coronary Artery Disease
|
0.200 |
Biomarker
|
disease |
LHGDN |
Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation.
|
19074676 |
2009 |
Coronary Artery Disease
|
0.200 |
Biomarker
|
disease |
BEFREE |
Coronary artery disease (CAD) is less common in African than Indian or White subjects and elevated plasminogen activator inhibitor (PAI)-1 levels may be a risk factor for CAD.
|
17467713 |
2008 |
Coronary Artery Disease
|
0.200 |
Biomarker
|
disease |
BEFREE |
To get a better insight into the role of hemostasis in coronary artery disease (CAD), we assessed the impact of von Willebrand factor (vWF), fibrinogen, thrombin-antithrombin (TAT) complexes, D-dimers, and plasmin-antiplasmin (PAP) complexes on the risk of cardiovascular event in a prospective cohort of CAD patients.
|
17023678 |
2006 |
Coronary Artery Disease
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The objective of our study is to evaluate the single locus and combined effects of three different genetic polymorphisms (methylenetetrahydrofolate reductase C677T polymorphism, plasminogen activator inhibitor 4G/5G polymorphism, and endothelial nitric oxide synthase 3-27 base pairs repeat polymorphism) on the presence and extent of coronary artery disease in patients with early-onset coronary artery disease.
|
16845248 |
2006 |
Coronary Artery Disease
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Levels of fibrinogen, factor VII (FVII), factor XIII (FXIII), plasminogen activator inhibitor (PAI)-1, and tissue plasminogen activator have been associated with coronary artery disease as have genetic polymorphisms.
|
11884298 |
2002 |
Coronary Artery Disease
|
0.200 |
Biomarker
|
disease |
BEFREE |
Increased circulating levels of type 1 plasminogen activator inhibitor (PAI-1) have been associated with coronary artery disease (CAD).
|
10235431 |
1999 |
Coronary Artery Disease
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Disturbances in fibrinolytic activity, such as increase in plasminogen activator inhibitor (PAI) activity, have been linked with an increased risk for coronary artery disease (CAD) and myocardial infarction (MI).
|
10494775 |
1999 |
Coronary Artery Disease
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In a logistic regression model, including age, BMI, cholesterol, sex, smoking, triglycerides, and plasminogen activator inhibitor antigen as covariates, genotype and fibrinogen levels were significantly associated with CAD.
|
8908392 |
1996 |